Compile Data Set for Download or QSAR
Report error Found 154 Enz. Inhib. hit(s) with all data for entry = 13204
TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766849(US20250268854, Example 63)
Affinity DataKd:  56.7nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766793(US20250268854, Example 1)
Affinity DataIC50: 75nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766874(US20250268854, Example 103)
Affinity DataKd:  83.2nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766887(US20250268854, Example 131)
Affinity DataKd:  97.6nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
Affinity DataKd:  101nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand Info
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766850(US20250268854, Example 64)
Affinity DataKd:  102nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766881(US20250268854, Example 114)
Affinity DataKd:  132nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766874(US20250268854, Example 103)
Affinity DataIC50: 160nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766879(US20250268854, Example 112)
Affinity DataKd:  183nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766849(US20250268854, Example 63)
Affinity DataIC50: 200nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766893(US20250268854, Example 137)
Affinity DataKd:  208nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766881(US20250268854, Example 114)
Affinity DataIC50: 220nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766901(US20250268854, Example 24)
Affinity DataKd:  230nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766821(US20250268854, Example 33)
Affinity DataKd:  242nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766813(US20250268854, Example 22)
Affinity DataIC50: 260nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766799(US20250268854, Example 8)
Affinity DataIC50: 270nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766812(US20250268854, Example 21)
Affinity DataIC50: 270nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766872(US20250268854, Example 101)
Affinity DataKd:  277nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766879(US20250268854, Example 112)
Affinity DataIC50: 280nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766872(US20250268854, Example 101)
Affinity DataIC50: 280nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766812(US20250268854, Example 21)
Affinity DataKd:  284nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766832((2S)-2-{[(2H-1,3-benzodioxol-4-yl)methyl]amino}-5,...)
Affinity DataKd:  285nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766900((2S)-2-{[(5-methoxypyridin-3-yl)methyl]amino}-5,5-...)
Affinity DataKd:  310nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766838(US20250268854, Example 51)
Affinity DataIC50: 320nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766880(US20250268854, Example 113)
Affinity DataIC50: 320nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766797(US20250268854, Example 6)
Affinity DataIC50: 330nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766828(US20250268854, Example 41)
Affinity DataIC50: 330nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766882(US20250268854, Example 115)
Affinity DataKd:  351nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766827(US20250268854, Example 39)
Affinity DataIC50: 360nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766877(US20250268854, Example 108)
Affinity DataIC50: 370nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766871(US20250268854, Example 100)
Affinity DataIC50: 380nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766887(US20250268854, Example 131)
Affinity DataIC50: 380nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766814(US20250268854, Example 23)
Affinity DataIC50: 390nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766868(US20250268854, Example 91)
Affinity DataIC50: 390nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766886(US20250268854, Example 129)
Affinity DataIC50: 390nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766796(US20250268854, Example 5)
Affinity DataKd:  396nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766796(US20250268854, Example 5)
Affinity DataKd:  396nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766796(US20250268854, Example 5)
Affinity DataKd:  396nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766821(US20250268854, Example 33)
Affinity DataIC50: 400nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766829(US20250268854, Example 42)
Affinity DataIC50: 400nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766873(US20250268854, Example 102)
Affinity DataKd:  407nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766842(US20250268854, Example 55)
Affinity DataIC50: 410nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766891(US20250268854, Example 135)
Affinity DataIC50: 420nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766882(US20250268854, Example 115)
Affinity DataIC50: 420nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766900((2S)-2-{[(5-methoxypyridin-3-yl)methyl]amino}-5,5-...)
Affinity DataIC50: 430nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetNeurotensin/neuromedin N(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766884(US20250268854, Example 117)
Affinity DataIC50: 430nMAssay Description:Compound affinity was determined by measuring the displacement of [3H]-neurotensin binding to h-Sortilin in SPA format. Total volume of 40 μl in 50 m...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766819(US20250268854, Example 31)
Affinity DataKd:  432nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766876(US20250268854, Example 107)
Affinity DataKd:  443nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766857(US20250268854, Example 75)
Affinity DataKd:  443nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

TargetSortilin(Human)
C/O Vesper Bio

US Patent
LigandPNGBDBM766818(US20250268854, Example 30)
Affinity DataKd:  450nMAssay Description:Compounds were screened at a final assay concentration of 1 μM and a final DMSO concentration was 1%. To achieve this, compounds were diluted in DMSO...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
12/8/2025
Entry Details
US Patent

Displayed 1 to 50 (of 154 total ) | Next | Last >>
Jump to: